• About
  • Policies
  • What is openaccess
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Biosystems engineering of prokaryotes with tumor-killing capacities

      Thumbnail
      View / Download
      612.0 Kb
      Author
      Kalyoncu, E.
      Olmez, T. T.
      Ozkan, A. D.
      Sarioglu, O. F.
      Date
      2016
      Source Title
      Current Pharmaceutical Design
      Print ISSN
      1381-6128
      Electronic ISSN
      1873-4286
      Publisher
      Bentham Science Publishers Ltd.
      Volume
      22
      Issue
      11
      Pages
      1521 - 1528
      Language
      English
      Type
      Article
      Item Usage Stats
      129
      views
      149
      downloads
      Abstract
      Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.
      Keywords
      Bifidobacterium
      Cancer therapy
      Clostridium
      Live vaccines
      Prodrug cleavage
      Salmonella
      Synthetic biology
      Antineoplastic agent
      Cytotoxic factor
      Drug carrier
      Flucytosine
      Fluorouracil
      Ganciclovir
      Live vaccine
      Probiotic agent
      Tretazicar
      Unclassified drug
      Vnp 20009
      Antibiotic therapy
      Antineoplastic activity
      Article
      Bacterial membrane
      Bacterial strain
      Bifidobacterium
      Cancer diagnosis
      Cancer recurrence
      Cancer therapy
      CD8+ T lymphocyte
      Cell infiltration
      Clostridium
      Colony forming unit
      Drug activation
      Drug delivery system
      Escherichia
      Gene transfer
      Genetic engineering
      Immune response
      Immunogenicity
      Metastasis
      Natural killer T cell
      Nonhuman
      Oxygen concentration
      Phase 2 clinical trial (topic)
      Priority journal
      Prokaryote
      Salmonella
      Target cell
      Tumor microenvironment
      Type III secretion system
      Animal
      Bacterium
      Biological therapy
      Cytology
      Genetics
      Human
      Metabolism
      Microbiology
      Neoplasms
      Pathophysiology
      Prokaryotic cell
      Animals
      Bacteria
      Biological therapy
      Humans
      Neoplasms
      Prokaryotic cells
      Permalink
      http://hdl.handle.net/11693/36631
      Published Version (Please cite this version)
      http://dx.doi.org/10.2174/1381612822666151210123752
      Collections
      • Institute of Materials Science and Nanotechnology (UNAM) 1775
      • Nanotechnology Research Center (NANOTAM) 1006
      Show full item record

      Related items

      Showing items related by title, author, creator and subject.

      • Thumbnail

        Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer 

        Ayvaci, M.U.S.; Shi J.; Alagoz O.; Lubner, S.J. (2013)
        Purpose. We evaluated the cost-effectiveness of adjuvant chemotherapy using 5-fluorouracil, leucovorin (5FU/LV), and oxaliplatin (FOLFOX) compared with 5FU/LV alone and 5FU/LV compared with observation alone for patients ...
      • Thumbnail

        Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade 

        Lotem, M.; Merims, S.; Frank, S.; Hamburger, T.; Nissan, A.; Kadouri, L.; Cohen, J.; Straussman, R.; Eisenberg, G.; Frankenburg, S.; Carmon, E.; Alaiyan, B.; Shneibaum, S.; Ayyildiz, Z. O.; Isbilen, M.; Senses, K. M.; Ron, I.; Steinberg, H.; Smith, Y.; Shiloni, E.; Gure, A. O.; Peretz, T. (Hindawi Limited, 2016)
        Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease ...
      • Thumbnail

        Early outcomes after transoral CO2 laser resection of laryngeal and hypopharyngeal squamous cell carcinoma: One centre's experience 

        Leong, S. C.; Kathan, C.; Mortimore, S. (Cambridge University Press, 2010)
        Objectives: To review early oncological outcomes following transoral CO2 laser resection of laryngeal and hypopharyngeal squamous cell carcinoma. Design: Retrospective review of hospital electronic database. Setting: Large ...

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartments

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 1771
      Copyright © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy